文献速递头颈部肿瘤放疗

术后高危头颈部腺样囊性癌:同步放化疗与单纯放疗的倾向性评分匹配分析

Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-03-17

本研究比较术后高危头颈部腺样囊性癌(ACC)患者接受同步放化疗(CCRT)与单纯放疗的疗效。前瞻性CCRT组55例与回顾性单纯放疗组160例,经1:1倾向性评分匹配后每组48例,中位随访51个月,两组总生存及局部区域无复发生存、远处转移无生存、无病生存均无显著差异。

要点

  • 术后IMRT基础上加同步多西他赛+奈达铂化疗未改善高危ACC患者的生存结局。
  • 匹配后5年OS率CCRT组90.7% vs 单纯放疗组84.3%,差异无统计学意义(p=0.331)。
  • LRRFS、DMFS、DFS在两组间均无显著差异(p分别为0.261、0.425、0.600)。

核心结论

  • 术后IMRT联合同步化疗在头颈部ACC患者中未带来LRRFS、DMFS、DFS或OS的生存获益。
  • 原文指出CCRT应在临床试验之外避免使用,并期待随机研究结果进一步阐明这一争议问题。

研究设计与样本

  • 前瞻性CCRT组55例与回顾性单纯放疗组160例术后头颈部ACC患者,入组条件为T3-4/N1-3 M0或R1/R2切除后。
  • 所有患者接受IMRT,CCRT组接受两周期同步多西他赛和奈达铂化疗。
  • 采用倾向性评分匹配(PSM)进行1:1匹配,匹配后每组48例,中位随访51个月,用Kaplan-Meier曲线和log-rank检验分析生存结局。

主要发现

  • 多因素Cox回归分析显示CCRT与OS无关联(HR=0.71,95%CI:0.24-2.08,p=0.537),与其他生存结局亦无关联。
  • 匹配后分析显示两组OS无显著差异(估计5年OS率:CCRT组90.7% vs 单纯放疗组84.3%,p=0.331)。
  • 匹配后LRRFS(p=0.261)、DMFS(p=0.425)、DFS(p=0.600)在两组间均无显著差异。
  • 匹配后多因素Cox回归分析同样显示CCRT与OS无关联(HR=0.29,95%CI:0.06-1.38,p=0.119),与其他生存结局亦无关联。

临床怎么用

  • 对于术后高危头颈部ACC患者,在IMRT基础上加用同步多西他赛和奈达铂化疗未显示生存获益。
  • 原文建议在临床试验之外避免使用CCRT。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of concurrent chemoradiotherapy (CCRT) in postoperative head and neck adenoid cystic carcinoma (ACC) remains controversial due to the limited evidence from randomized trials. This study assessed the effectiveness of CCRT by comparing a prospective CCRT group with a retrospective radiation(RT) alone group using propensity score matching (PSM). METHODS AND MATERIALS: Postoperative head and neck ACC patients with T3-4/N1-3 M0 disease or after R1/R2 resection were enrolled. All patients underwent intensity-modulated radiation therapy (IMRT), and CCRT group received two cycles of concurrent docetaxel and nedaplatin. To ensure comparability, PSM were utilized. Following PSM, survival outcomes were analyzed using Kaplan-Meier curves and compared using the log-rank test. RESULTS: A prospective CCRT group of 55 patients and a retrospective RT alone group of 160 patients were included. The multivariate Cox regression analysis showed no association between CCRT and overall survival (OS) (hazard ratio [HR] = 0.71, 95 %CI: 0.24-2.08, p = 0.537), or other survival outcomes. To mitigate potential confounding factors, a 1: 1 PSM analysis was performed. With a median follow-up of 51 months, post-PSM analysis (including 48 patients in each group) indicated no significant differences in OS (estimated 5-year OS rates: 90.7 % versus 84.3 %, p = 0.331), locoregional recurrence-free survival (LRRFS) (p = 0.261), distant metastasis-free survival (DMFS) (p = 0.425), or disease-free survival (DFS) (p = 0.600) between two groups. The multivariate Cox regression analysis also showed no association between CCRT and OS (HR = 0.29, 95 %CI: 0.06-1.38, p = 0.119), or other survival outcomes. CONCLUSION: The addition of concurrent chemotherapy to postoperative IMRT did not confer a survival benefit in terms of LRRFS, DMFS, DFS, or OS in patients with head and neck ACC. Upcoming results from randomized studies are anticipated to shed more light on this debated issue. CCRT should be avoided outside of clinical trials.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dou S, Wang X, Xiao Y, et al. Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis. Clin Transl Radiat Oncol. 2025. PMID: 40225788. doi:10.1016/j.ctro.2025.100945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。